AMT Holding Terug naar discussie overzicht

uniQure Q&A

1. flosz 9 maart 2012 18:53

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   uniQure Q&A
   For more information in relation to any of the matters scheduled for the extraordinary general meeting of shareholders ("Extraordinary General Meeting") of Amsterdam Molecular Therapeutics (AMT) Holding N.V ("AMT") to be held Friday 30 March 2012 at 11:00 CET at Academisch Medisch Centrum, College Zaal 2, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands please review the notice, agenda and explanatory notes to the agenda as well as the shareholders circular that have been made available on AMT's website (www.amtbiopharma.com and that are also available in hard copy at AMT's offices at Meibergdreef 61 (1105 BA) Amsterdam, The Netherlands.
   1. When and where will the extraordinary general meeting of
   shareholders ("Extraordinary General Meeting") of Amsterdam
   Molecular Therapeutics (AMT) Holding N.V. ("AMT") be held?
   The Extraordinary General Meeting of AMT will be held on Friday 30 March 2012 at 11:00
   CET at Academisch Medisch Centrum, College Zaal 2, Meibergdreef 9, 1105 AZ
   Amsterdam, The Netherlands.
   
   2. Who are entitled to vote and/or attend the Extraordinary
   General Meeting of AMT
   In short, anyone who is registered as a shareholder on 2 March 2012, and who has
   registered for participation in the Extraordinary General Meeting.
   For full details, please see the notice of the Extraordinary General Meeting.
   
   3. How do I register for participation in the Extraordinary General
   Meeting?
   A shareholder who chooses to participate in the Extraordinary General Meeting may apply
   via his bank in writing until 15:00 CET on 27 March 2012, to Kempen & Co N.V.,
   Beethovenstraat 300, 1077 WZ Amsterdam, The Netherlands. With the application a
   confirmation must be submitted from the bank through which the shares are held that the
   shares concerned were registered in the name of that holder on 2 March 2012.
   The acknowledgement of receipt provided will be valid as an attendance card to the
   meeting. Kempen & Co N.V. shall arrange for deposit of these applications at AMT’s office address.
   Shareholders holding non-traded shares and who registered as a shareholder in AMT's
   shareholder register on 2 March 2012 may apply to AMT (telefax number: +31 (0)20
   5669272) in writing until 15:00 CET on 27 March 201
   For full details, please see the notice of the Extraordinary General Meeting.
   
   4. Can I appoint someone to represent me at the Extraordinary
   General Meeting?
   
   Yes - a shareholder who chooses to have himself represented at the Extraordinary
   General Meeting by a third party must – in addition to the application requirements (see
   question 3) – provide AMT with a proxy to that effect.
   For the granting of a proxy, shareholders are required to use a form, which can be
   obtained from 15 March 2012 via Kempen & Co N.V., (telefax number: +31 (0)20
   3489549 or e-mail address: proxyvoting@kempen.nl) or from AMT (telephone number:
   +31 (0)20 5667394; telefax number: +31 (0)20 5669272) and can then also be
   downloaded from AMT's website (www. www.amtbiopharma.com).
   The completed form, duly completed by the shareholder, must have been received by
   Kempen & Co N.V or by AMT by 15:00 CET on 27 March 2012 ultimately.
   Receipt of proxy forms can be rejected after this time deadline.
   
   5. Where can I find more information? For example on the
   agenda and the resolutions proposed to the Extraordinary
   General Meeting as well as the proposed public-to-private and
   financing transaction with uniQure (the "Transaction")?
   On AMT's website (www.amtbiopharma.com) the notice, agenda and explanatory notes to
   the agenda as well as a shareholders circular are made available. Hard copies are
   available at AMT's offices at Meibergdreef 61 (1105 BA) Amsterdam, The Netherlands
   and will be available at the Extraordinary General Meeting.
   Furthermore, AMT will hold two informational meetings for shareholders at its offices on
   23 February 23 and 20 March 2012. The 23 February 2012 meeting will be from 11.00 –
   13:00 at AMT's offices, 61 Meibergdreef in Amsterdam. Details of the 20 March 2012
   meeting will be posted on AMT's website www.amtbiopharma.com
   During these meetings, Ferdinand Verdonck chairman of the Special Committee for the
   evaluation of the transaction, Jörn Aldag (CEO), Piers Morgan (CFO) Dr. Carlos Camozzi
   (Chief Medical Officer) will be on hand to answer investor questions.
   You can sign up for this meeting by sending an e-mail to amtir@amtbiopharma.com. For
   this meeting there is a maximum capacity of 30 people, so if you want to attend this
   meeting, it is necessary to register a.s.a.p. .
   
   6. How will I be informed if an Alternative Offer is made?
   If in the period starting on 17 February 2012 and ending on 14 March 2012 (the
   "Alternative Offer Period") AMT receives one or more written bona fide unconditional
   offers by any third party for AMT or its business or a significant part thereof that may be a
   realistic and credible alternative to the Transaction for AMT's shareholders and other
   stakeholders (each such offer an "Alternative Offer"), AMT will as soon as possible
   publicly announce that the Alternative Offer was made and the terms and conditions
   thereof.
   
   7. In the event an Alternative Offer is made, will I be able to give
   specific voting instruction in relation to the disposal of AMT's
   business to uniQure and the Alternative Offer?
   Yes – for the granting of a proxy, a form shall be made available from 15 March 2012.
   The proxy shall include the possibility to give specific voting instructions on the proposal
   to dispose AMT's business to uniQure and any Alternative Offer that may have been
   made (see question 6 as well).
   
   8. What will AMT do in the event no Alternative Offer is made?
   In the event no Alternative Offer is made, and subject to the disposal of AMT's business to
   uniQure being approved, AMT will pursue the disposal of AMT's business to uniQure.
   
   9. What will AMT do in the event an Alternative Offer is made and
   both the disposal of AMT's business to uniQure and an
   Alternative Offer are approved?
   If the Extraordinary General Meeting approves the disposal of AMT's business to uniQure
   as well as an Alternative Offer, AMT shall pursue the transaction in favour of which the
   highest majority of the votes were cast.
   
   10. What will AMT do in the event an Alternative Offer is made and
   the disposal of AMT's business to uniQure is approved and an
   Alternative Offer is not approved?
   If the Extraordinary General Meeting approves the disposal of AMT's business to uniQure
   but does not approve the Alternative Offer, AMT shall pursue the disposal of AMT's
   business to uniQure.
   
   11. What will AMT do in the event an Alternative Offer is made and
   the disposal of AMT's business to uniQure is disapproved and
   the Alternative Offer is approved?
   If the Extraordinary General Meeting does not approve the disposal of AMT's business to
   uniQure but approves the Alternative Offer, AMT shall pursue the Alternative Offer.
   
   Meer via : www.amtbiopharma.com/uploads/uniQureQ...
   
2. flosz 9 maart 2012 19:02

   auteur info

   • flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 22 jun 2023

   • Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   28. Will uniQure DRs be listed on a stock exchange or similar
   market?
   No - uniQure DRs will not be admitted to trading on a regulated market. uniQure will look
   into the possibilities of facilitating the trade of uniQure DRs.
   
   29. Will I be able to sell or trade in the uniQure DRs
   Yes – uniQure DRs will be freely transferable and, provided that you yourself www.youtube.com/watch?v=kw02oX3_uC8 find a buyer
   for such uniQure DRs at a price to be agreed upon between you and such buyer, can be
   sold (but see question 28 as well).
   
   30. If I want to sell my uniQure DRs how will I determine the price?
   As a result of the fact that neither the uniQure DRs nor the (class A or Class B) ordinary
   shares in uniQure will be admitted to trading on a regulated market www.youtube.com/watch?v=H3HI4xKr36Q there will be no price
   published. Consequently you will have to agree a price with the buyer of your uniQure
   DRs (but see question 28 and 29 as well).
   
3. Prof. Dollar 9 maart 2012 22:11

   auteur info

   • Prof. Dollar

     Lid sinds: 04 mrt 2011

     Laatste bezoek: 07 mei 2024

   • Aanbevelingen

     Ontvangen: 194

     Gegeven: 53

   •    Aantal posts: 2.284

   "The Trust Foundation shall be party to the uniQure Shareholders Agreement. The uniQure Shareholders Agreement shall include a so-called "drag arrangement", which may oblige the Trust Foundation to sell the Class B ordinary shares underlying the uniQure DRs. Although in such situation the Trust Foundation shall be obliged to distribute the sale proceeds for such shares to the holders of uniQure DRs, the drag arrangement being enforced against the Trust Foundation will effectively result in your investment in the Business being discontinued and sold of at a price and a moment that is out of your control."
   
   Voor de kleine belegger wordt het een moeilijke keus.
   
   - Nu verkopen met waarschijnlijk groot verlies. Geen gunstige optie (verkopen kan tot +/- 23 april).
   
   of
   
   - Zittenblijven totdat uniQure in z'n geheel wordt verkocht. Dit kan over tien jaar zijn of helemaal nooit. Daarbij blijft het gissen naar de waarde en tussentijdse verwatering. Geen gunstige optie.
   
   - Zittenblijven tot eind dit jaar. Hopen dat Glybera goedkeuring heeft gekregen, dat er voortzetting komt buiten de EU en dat partners andere programma's mee financieren. Ook dit zou een verkoopmoment van uniQure in z'n geheel kunnen zijn. Zou Forbion hiermee akkoord gaan? Maar ook bij geen verkoop raak je in dit scenario je DR's mogelijk wel tegen een redelijke prijs kwijt.
   
   Ik ben bang dat een jaar uitzitten de enige optie dat enigszins gunstig kan uitpakken. En dan nog moet je zelf voor een koper zorgen die wil kopen voor een goede prijs.
   
   Wat zijn jou ideeën flosz?
   
   
4. [verwijderd] 11 maart 2012 21:32

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Nou heren dit vind ik wel somber hoor.
   Volgens mij gaat het maximaal 5 jaar duren, maar wellicht 3 voordat het hemofilie programma klaar is. Voor die tijd gebeurt er vast iets waardoor een verkoopmoment ontstaat. Nogmaals, de bestuurders & directie hebben ook DR's. Die willen ook cashen. Je moet alleen je geld niet nodig hebben....
   Fiscaal is dit ook nog wel aantrekkelijk, want wat is de waarde van niet genoteerde DR's in box 3? Wie het weet mag het zeggen....
5. [verwijderd] 12 maart 2012 09:20

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Vind dat ze meer opties moeten bieden aan kleine beleggers.. Vreemd dat ze dan niet gewoon als aanvullende optie die 0,614 uitkeren per aandeel.
   Ik heb weinig keus voor mijn gevoel als er een stel in de ijskast te leggen (dit nog even los van wel of niet vertrouwen in toekomst, aangezien die niet concreet genoeg is)
   
   Is de VEB nog bezig met het behartigen van onze belangen?
6. Prof. Dollar 12 maart 2012 12:29

   auteur info

   • Prof. Dollar

     Lid sinds: 04 mrt 2011

     Laatste bezoek: 07 mei 2024

   • Aanbevelingen

     Ontvangen: 194

     Gegeven: 53

   •    Aantal posts: 2.284

   Eigenlijk zou er de regel moeten komen dat bij uitbreiding aandelen, er naar verhouding DR's opgekocht moet worden.